Targeted Oncology· @TargetedOnc · X·· 14 小时前评分70
正文 · 原文
INTerpath-001 raises exciting questions:
Will improved RFS/DMFS translate into OS benefit?
How does this compare with neoadjuvant immunotherapy?
Can personalized vaccines be manufactured quickly, affordably and at scale?
Innovation must also be deliverable. #ESMO26
59 浏览 · 1 赞 · 0 转发 · 1 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org帖内回复
- WaSaBi@dtabait
@TargetedOnc Not enough events to determine OS.
来源：Targeted Oncology · x.com